Publication details

Novel sulfonamide incorporating piperazine, aminoalcohol and 1,3,5-triazine structural motifs with carbonic anhydrase I, II and IX inhibitory action

Authors

HAVRÁNKOVÁ Eva CSÖLLEI Jozef VULLO Daniela GARAJ Vladimír PAZDERA Pavel SUPURAN Claudiu T.

Year of publication 2018
Type Article in Periodical
Magazine / Source Bioorganic Chemistry
MU Faculty or unit

Faculty of Science

Citation
web https://doi.org/10.1016/j.bioorg.2017.12.034
Doi http://dx.doi.org/10.1016/j.bioorg.2017.12.034
Field Organic chemistry
Keywords Sym-Triazine Benzene sulfonamides; Carbonic anhydrase; Enzyme inhibition; Isoform selectivity;
Description A new series of s-triazine derivatives incorporating sulfanilamide, homosulfanilamide, 4-aminoethylbenzenesulfonamide and piperazine or aminoalcohol structural motifs is reported. Molecular docking was exploited to select compounds from virtual combinatorial library for synthesis and subsequent biological evaluation. The compounds were prepared by using step by step nucleophilic substitution of chlorine atoms from cyanuric chloride (2,4,6-trichloro-1,3,5-triazine). The compounds were tested as inhibitors of physiologically relevant carbonic anhydrase (CA, EC 4.2.1.1) isoforms. Specifically, against the cytosolic hCA I, II and tumor-associated hCA IX. These compounds show appreciable inhibition. hCA I was inhibited with KIs in the range of 8.5–2679.1 nM, hCA II with KIs in the range of 4.8–380.5 nM and hCA IX with KIs in the range of 0.4–307.7 nM. As other similar derivatives, some of the compounds showed good or excellent selectivity ratios for inhibiting hCA IX over hCA II, of 3.5–18.5. 4-[({4-Chloro-6-[(4-hydroxyphenyl)amino]-1,3,5-triazin-2-yl}amino)methyl] benzene sulfonamide demonstrated subnanomolar affinity for hCA IX (0.4 nM) and selectivity (18.50) over the cytosolic isoforms. This series of compounds may be of interest for the development of new, unconventional anticancer drugs targeting hypoxia-induced CA isoforms such as CA IX.

You are running an old browser version. We recommend updating your browser to its latest version.

More info